TapewireFind a company

person · Reporting owner

FLAVIN JOHN L

Disclosed activity across 1 company

Tapewire entity
56110
SEC CIK
0001126556

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Pyxis Oncology, Inc.PYXS · Entity 5986DirectorMarch 24, 2026March 25, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Pyxis Oncology, Inc.

Report date March 24, 2026 · Filed March 25, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-03-24Direct45,867 Reported balance After 2026-03-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-03-24 · Grant · Acquired 45,867 · Balance 45,867

F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 24, 2026 Filed Mar 25, 2026 17:10 UTC Pyxis Oncology, Inc. PYXS · Entity 5986 GrantStock Option (Right to Buy) · Derivative 45,867 $0.00 Strike: $1.36 $0.00
Disclosure

SEC source: 0001193125-26-124348 · ownership.xml · derivative · entry 1

FLAVIN JOHN L · CIK 0001126556 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,867

Underlying: Common Stock · 45,867 shares

Expires 2036-03-24

F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 08:55 UTC Pyxis Oncology, Inc. PYXS · Entity 5986 GrantStock Option (Right to Buy) · Derivative 36,979 $0.98 Strike: $0.98 $36,239.42
Disclosure

SEC source: 0000950170-25-048892 · ownership.xml · derivative · entry 1

FLAVIN JOHN L · CIK 0001126556 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,979

Underlying: Common Stock · 36,979 shares

Expires 2035-03-31

F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

Read SEC document
March 26, 2024 Filed Mar 28, 2024 16:33 UTC Pyxis Oncology, Inc. PYXS · Entity 5986 GrantCommon Stock 35,219 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-038104 · ownership.xml · nonDerivative · entry 1

FLAVIN JOHN L · CIK 0001126556 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 413,015

F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

Read SEC document
March 24, 2023 Filed Mar 28, 2023 16:43 UTC Pyxis Oncology, Inc. PYXS · Entity 5986 GrantCommon Stock 139,355 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-021407 · doc4.xml · nonDerivative · entry 1

FLAVIN JOHN L · CIK 0001126556 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 377,796

F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

Read SEC document
March 31, 2022 Filed Apr 4, 2022 16:16 UTC Pyxis Oncology, Inc. PYXS · Entity 5986 GrantCommon Stock 66,831 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-012921 · form4.xml · nonDerivative · entry 1

FLAVIN JOHN L · CIK 0001126556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,441

F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

Read SEC document
October 13, 2021 Filed Oct 15, 2021 17:35 UTC Pyxis Oncology, Inc. PYXS · Entity 5986 ConversionSeries B Convertible Preferred Stock · Derivative 15,190 $0.00 $0.00
Disclosure

SEC source: 0001140361-21-034643 · form4.xml · derivative · entry 2

FLAVIN JOHN L · CIK 0001126556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,388 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

Read SEC document
October 13, 2021 Filed Oct 15, 2021 17:35 UTC Pyxis Oncology, Inc. PYXS · Entity 5986 ConversionCommon Stock 2,388 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-21-034643 · form4.xml · nonDerivative · entry 1

FLAVIN JOHN L · CIK 0001126556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,610

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

F2 · balance_after: Includes 47,593 shares of restricted stock that are subject to vesting in six, substantially-equal quarterly installments beginning October 22, 2021, subject to the reporting person's continued service through the applicable vesting date.

Read SEC document
October 07, 2021 Filed Oct 12, 2021 19:47 UTC Pyxis Oncology, Inc. PYXS · Entity 5986 GrantStock Option (Right to buy) · Derivative 42,191 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0001140361-21-034426 · form4.xml · derivative · entry 1

FLAVIN JOHN L · CIK 0001126556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,191

Underlying: Common Stock · 42,191 shares

Expires 2031-10-07

F1 · derivative.exercise_date: These stock options vest as to 1/3 of the shares covered by the option on each annual general meeting of the Issuer's stockholders following the October 7, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.